Oncology News | pharmaphorum

News

Rebranded Servier eyes €3bn in cancer drug sales by 2030

Servier is already in the process of transforming itself into a much bigger player in cancer, and has just tripled its sales objectives for the category.

News

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

GSK's latecomer to the PD-1/PD-L1 inhibitor category Jemperli has barely started to bring in revenues, and is a world away from the company's hopes of blockbuster revenues by 2031.

News

PARP rivals close in on AZ and Merck's market leading Lynpar...

AstraZeneca and Merck & Co's Lynparza has been the undisputed market leader in the PARP inhibitor category for some years, but would-be competitors continue to chip away at its market s

Views & Analysis

How data is crucial to the relaunch of the Cancer Moonshot

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot.

News

Roche gets FDA approval for HER2 breast cancer diagnostic

The FDA has approved Swiss pharmaceutical company Roche’s first companion diagnostic for identifying those patients with HER2 low-metastatic breast cancer who are eligible for ENHERTU.

News

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

Roche's Genentech division has formed an R&D partnership with Arsenal Biosciences focusing on developing and refining the biotech's programmable T cell-based therapies platform.

Rebranded Servier eyes €3bn in cancer drug sales by 2030

GSK's Jemperli/TIM-3 immuno-oncology combo moves to ph3

PARP rivals close in on AZ and Merck's market leading Lynpar...

How data is crucial to the relaunch of the Cancer Moonshot

Roche gets FDA approval for HER2 breast cancer diagnostic

Roche puts $70m into ArsenalBio's programmable T-cell platfo...

J&J abandons trial of atopic dermatitis drug

How to meet your physicians where they are online

News

Editor's Picks